Vaxcyte (PCVX) Stock Overview
A clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
PCVX Community Fair Values
Create NarrativeSee what 14 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Vaxcyte, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$59.47 |
| 52 Week High | US$65.00 |
| 52 Week Low | US$30.81 |
| Beta | 1.22 |
| 1 Month Change | 2.41% |
| 3 Month Change | 20.00% |
| 1 Year Change | 84.86% |
| 3 Year Change | 14.98% |
| 5 Year Change | 134.50% |
| Change since IPO | 127.42% |
Recent News & Updates
Recent updates
Vaxcyte: Not Enough Safety Margin With Current Price
Summary Vaxcyte is a clinical-stage vaccine leader with VAX-31, targeting both adults and infants with broad pneumococcal coverage. My valuation model yields a $39.48/share post-dilution target, well below the current $58.07, supporting a 'Sell' rating. Key risks include inevitable dilution, execution challenges, and entrenched Big Pharma competitors threatening market share assumptions. OPUS-1 Phase 3 topline in Q4 is the pivotal near-term catalyst; flawless execution is critical to justify current valuation. Read the full article on Seeking AlphaVaxcyte (PCVX) Stock Could Be 52.8% Undervalued After VAX A1 Enters Phase 1
Vaxcyte (PCVX) recently started dosing participants in a Phase 1 trial of VAX-A1, its investigational Group A Streptococcus vaccine. This development gives investors a fresh clinical milestone to weigh alongside the stock’s recent performance. See our latest analysis for Vaxcyte. The recent VAX-A1 trial news comes as Vaxcyte’s 7-day share price return of 8.39% and 30-day share price return of 8.75% contrast with a softer 90-day share price return. The 1-year total shareholder return of 56.50%...
Future Late Stage Vaccine Programs And Manufacturing Capacity Will Drive Long Term Opportunity
Catalysts About Vaxcyte Vaxcyte is a vaccine company focused on developing broader-coverage pneumococcal and Group A Strep vaccines for adult and pediatric use. What are the underlying business or industry changes driving this perspective?
Late Stage Vaccine Programs And New Manufacturing Capacity Will Underpin Long Term Upside
Catalysts About Vaxcyte Vaxcyte is a vaccine company focused on pneumococcal conjugate vaccines and a Group A Strep program, using a carrier sparing platform to target broad disease coverage. What are the underlying business or industry changes driving this perspective?
Late Stage Vaccine Trials And Manufacturing Buildout Will Shape Balanced Long Term Outlook
Catalysts About Vaxcyte Vaxcyte is a vaccine company developing pneumococcal conjugate vaccines and a Group A Strep candidate using a carrier sparing platform and large scale manufacturing infrastructure. What are the underlying business or industry changes driving this perspective?Vaxcyte: Plunge On FDA Top Regulator Resigning Generates Buying Opportunity
Summary Vaxcyte, Inc.'s positive results achieved from phase 2 dose-finding study using VAX-24 for the prevention of invasive pneumococcal disease in infants; Further post 4 dose data expected 2nd of 2025. It is expected that the 7 major pneumococcal disease markets are to reach a value of $11.6 billion by 2035. VAX-24 goes beyond that of Prevnar 20 in terms of targeting 4 more serotypes than it. PCVX is attempting to expand its program in the prevention of IPD with candidates VAX-31 and VAX-XL; The goal is broaden the disease that can be targeted. Read the full article on Seeking AlphaVaxcyte Aims To Outshine Pfizer With Bold VAX-31 Strategy
Summary Vaxcyte's stock surged 68% since August 2023, driven by progress with its pneumococcal conjugate vaccine candidates, VAX-24 and VAX-31. VAX-31, covering 95.6% of serotypes, has been selected over VAX-24 for Phase 3 trials, with topline data expected in 2026. Vaxcyte's robust financial position, with over $3 billion in cash and investments, supports its strategic flexibility and extended timelines. The expanded market guidelines and projected PCV market growth to $12 billion bolster Vaxcyte's potential, with VAX-31's NPV estimated at $13.5 billion upon approval. Despite recent weakness, maintaining a buy rating based on upcoming Phase 3 catalyst and strong cash position, though high valuation presents risks. Read the full article on Seeking AlphaVaxcyte: Stunning PCV Data Readout Suggests Vaccine Maker Is A Strong Buy
Summary Vaxcyte's stock surged this week due to promising Phase 1/2 data for its VAX-31 vaccine, showing superior immune responses compared to Pfizer's Prevnar 20. VAX-31 targets 31 strains, covering over 95% of IPD in U.S. adults, with Phase 3 trials expected to deliver top line data by mid-2026. Despite competition from Merck and GSK, Vaxcyte's innovative XpressCF platform offers a significant competitive edge in the growing PCV market. Investors should consider potential risks and wait for market stabilization post-fundraising, but the long-term upside remains compelling with possible +75% upside in play, in my view. There are some risks to consider - length of time to potential approval the most prominent - but it's rare to see such a compelling data set when market incumbents are so established. Read the full article on Seeking AlphaShareholder Returns
| PCVX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.8% | -5.3% | -1.0% |
| 1Y | 84.9% | 37.0% | 14.1% |
Return vs Industry: PCVX exceeded the US Biotechs industry which returned 37% over the past year.
Return vs Market: PCVX exceeded the US Market which returned 14.1% over the past year.
Price Volatility
| PCVX volatility | |
|---|---|
| PCVX Average Weekly Movement | 5.7% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: PCVX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: PCVX's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 507 | Grant Pickering | vaxcyte.com |
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine.
Vaxcyte, Inc. Fundamentals Summary
| PCVX fundamental statistics | |
|---|---|
| Market cap | US$8.85b |
| Earnings (TTM) | -US$1.06b |
| Revenue (TTM) | n/a |
Is PCVX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PCVX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$1.06b |
| Earnings | -US$1.06b |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -7.15 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did PCVX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/13 03:35 |
| End of Day Share Price | 2026/09/11 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vaxcyte, Inc. is covered by 15 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Matthew Gerberry | BofA Global Research |
| Thomas Shrader | BTIG |
| Carter Gould | Cantor Fitzgerald & Co. |